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Lapatinib potentiates cytotoxicity 
of  YM155 in neuroblastoma via 
inhibition of the ABCB1 efflux 
transporter
Branka Radic-Sarikas 1, Melinda Halasz  2,3, Kilian V. M. Huber  1, Georg E. Winter1, Kalliopi 
P. Tsafou5, Theodore Papamarkou  6, Søren Brunak5, Walter Kolch  2,3,4 & Giulio Superti-
Furga  1,7
Adverse side effects of cancer agents are of great concern in the context of childhood tumors where 
they can reduce the quality of life in young patients and cause life-long adverse effects. Synergistic 
drug combinations can lessen potential toxic side effects through lower dosing and simultaneously 
help to overcome drug resistance. Neuroblastoma is the most common cancer in infancy and extremely 
heterogeneous in clinical presentation and features. Applying a systematic pairwise drug combination 
screen we observed a highly potent synergy in neuroblastoma cells between the EGFR kinase inhibitor 
lapatinib and the anticancer compound YM155 that is preserved across several neuroblastoma variants. 
Mechanistically, the synergy was based on a lapatinib induced inhibition of the multidrug-resistance 
efflux transporter ABCB1, which is frequently expressed in resistant neuroblastoma cells, which allowed 
prolonged and elevated cytotoxicity of YM155. In addition, the drug combination (i.e. lapatinib plus 
YM155) decreased neuroblastoma tumor size in an in vivo model.
As a consequence of aggressive therapies, many childhood cancer survivors experience long-term adverse effects 
that negatively influence their quality of life. Neuroblastoma (NB) is the most common cancer in infancy1 and the 
most common extracranial solid tumor in children2–4 which can occur anywhere along the sympathetic nervous 
system. It is a remarkably heterogeneous disease, in both clinical behavior and genotype5. The main prognos-
tic factors are the status of the MYCN (v-Myc avian myelocytomatosis viral oncogene neuroblastoma derived 
homolog) and NTRK1 expression (encoding TRKA, a member of the TRK family of neurotrophin receptors), 
predisposing to poor and good prognosis, respectively. Furthermore, a range of different chromosomal aberra-
tions are considered for risk stratification. It has been suggested that a major cause of therapeutic failure in neuro-
blastoma is the occurrence of resistance6. Overexpression of drug efflux transporters is one of the most common 
mechanisms of resistance7. In support of this hypothesis a number of ATP-binding cassette transporters (ABC 
transporters), including the multidrug-resistance transporter ABCB1, are known to be transcriptionally regu-
lated by MYCN in neuroblastoma cells8, 9, thus supporting a drug-resistance role of ABCB1 in this tumor type. 
Overexpression of ABC transporters leads to intrinsic resistance to various therapeutics10, 11 and it is associated 
with poor clinical outcome12. Combination therapies can overcome these issues. A synergistic drug combination 
is more potent than equally effective doses of its components13, thus providing additional benefit to a patient 
over a simple increase in single component dosages. In this study, using a combinatorial screening approach, we 
identified a combination of the cytotoxic anticancer compound YM155 and the kinase inhibitor lapatinib to act 
highly synergistically in neuroblastoma including cells resistant to YM155. Further mechanistic studies revealed 
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the ABCB1 transporter as a molecular determinant for this newly discovered synergy which we found to be con-
served across neuroblastoma subtypes. We show that both intrinsic and/or acquired resistance to YM155 could 
be reverted by the efflux inhibition by lapatinib.
Results
Combinatorial screen reveals high degree of synergy between YM155 and lapatinib in neuro-
blastoma regardless of the MYCN and TRKA status. Following a previously established concentra-
tion matrix-based combinatorial drug screen approach (Winter et al.14) we tested a carefully selected library 
comprised of targeted anticancer agents proved to be safe in patients or already approved for therapeutic use in 
pairwise combinations using SH-SY5Y neuroblastoma cells line as a model system (Fig. 1A, Table S1). First, we 
assessed the IC50 values for the initial drug library in SH-SY5Y. Next, we selected a small combinatorial sub-li-
brary of drugs that potently inhibited cancer cell growth, because of the rapid augmentation of the number of data 
points with every compound in a concentration matrix–based screening design where each drug is combined 
Figure 1. YM155 and lapatinib show high degree of synergy in neuroblastoma regardless of the MYCN and 
TRKA status. (A) Overview of the drug library used in the concentration matrix-based combination screen. 
(B) Chemical structures of lapatinib and YM155. (C) Microarray-based gene expression profiling. Bar graphs 
are showing the number of significantly upregulated and downregulated genes in each condition. (D) Colony 
formation assay; YM155 (black border) was used at 1/16 IC50 concentration (15 nM), lapatinib (gray border) 
at 1/8 IC50 (1 µM). Combination treatment (blue border): 15 nM YM155 and 1 µM lapatinib. DMSO (no 
border) treated cells were used as a control. Data shown as mean ± s.e.m. and images are representative of 
three individual experiments (ANOVA, **P < 0.01). (E) Heatmap of CI values in the YM155 and lapatinib 
combination matrix, indicating a strong synergistic interaction. Data represent the mean of triplicates. (F,G) 
Synergistic effect is preserved in NTRK1 and MYCN highly expressed state. (F) Left, overexpression and 
activation of TRKA signaling in SH-SY5Y; right, heatmap of CI values in the combination matrix; data represent 
the mean of triplicates. (G) Left, overexpression of MYCN in SH-SY5Y and levels of MYCN protein in the 
IMR5–75 MYCN amplified cell line; right, heatmap of CI values in the combination matrix; data represent the 
mean of triplicates.
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with another (a total of 18 compounds; Fig. 1A, Table S1). The type of drug-drug interaction was assessed using 
the combination index (CI) method15 a quantification of the Loewe additivity approach16. Analyzing 153 drug 
combinations in five concentration points each, we found a strong synergy between the dual EGFR/HER2 kinase 
inhibitor lapatinib and the “survivin suppressant” sepantronium bromide (YM155) (Fig. 1B). In 2007, lapatinib 
(Tykerb/Tyverb®) was approved by the FDA for combination therapy in breast cancer and in 2010 for HER2 
positive metastatic breast cancer. It was also in phase II clinical trials for malignant conditions in young patients 
such as refractory CNS malignancies17. YM155 causes downregulation of survivin and the induction of DNA 
damage18, 19, and it was evaluated in various clinical trials for single and combination therapy in prostate cancer, 
lymphoma and melanoma20, 21.
Using a microarray-based gene expression profiling approach, we observed marked global expression changes 
upon combinatorial treatment in SH-SY5Y, but little or no significantly regulated genes when SH-SY5Y cells were 
treated with either drug alone (Fig. 1C). We confirmed the synergy seen on a transcriptional level in a long-term 
colony formation assay in the SH-SY5Y cell line (Fig. 1D), where the compounds were applied at 10- or 15-fold 
lower concentrations than their respective IC50s (IC50 for YM155 in SH-SY5Y was 249 nM, while IC50 for lapat-
inib was 6.8 µM). Not surprisingly, single drug treatments at these concentrations were unable to cause cell death. 
However, the combination significantly inhibited colony formation and had a profound effect on cell viability. 
Moreover, the synergy occurred in the lower, clinically relevant dose range, at a concentration of lapatinib that is 
achievable in pediatric patients and considerably lower than the serum limit22–24. Whereas lapatinib is an orally 
active drug, the pharmacokinetic profile of YM155 is less favorable; still, the plasma concentration that corre-
sponds to the concentration of YM155 where we observed high synergy is achievable and well tolerated in adult 
patients20. In contrast to MYCN overexpressing tumors, neuroblastomas that express NTRK1 are likely to regress 
spontaneously or differentiate, if the TRKA ligand nerve growth factor (NGF) is expressed in the tumor25. Thus, 
a promising approach to induce spontaneous regression is via TRKA pathway stimulation26. When we treated 
the SH-SY5Y cells expressing NTRK127 with the two drugs, and stimulated cells with NGF, the synergy between 
YM155 and lapatinib was again detected, although slightly reduced compared to the wild type cells (Fig. 1E and F). 
These results suggest that the differentiation and apoptosis promoting functions of NGF overlap with the effects 
of the drug combination YM155 and lapatinib. The MYCN proto-oncogene is frequently amplified in neuroblas-
toma and correlates with advanced disease stage as well as aggressiveness and a poor prognosis22, 24, 26. The synergy 
screen was performed using the SH-SY5Y wild type cells which have no MYCN gene amplification. Thus, to test 
whether activation of MYCN affects the synergy observed for lapatinib and YM155 we used a genetically modified 
SH-SY5Y derivative cell line that allows for the inducible overexpression of this gene. The high degree of synergy 
was retained in MYCN overexpressing SH-SY5Y cells, and importantly, we detected a synergistic effect in the 
patient-derived and MYCN-amplified IMR5–75 cell line (Fig. 1G). The synergy between lapatinib and YM155 
occurred regardless of the MYCN and NTRK1 status.
Synergistic effect is a consequence of a blocked efflux of YM155 by lapatinib. In order to examine 
whether EGFR/HER2 inhibition is required for the synergistic effect with YM155, we used other EGFR or EGFR/
HER2 inhibitors instead of lapatinib. Interestingly, only some of them acted similarly, while others did not result 
in a synergistic effect (data not shown). This was suggestive of the fact that the inhibition of the EGFR/HER2 
signaling pathway was not critical for the response. Therefore, we investigated alternative possibilities. Lapatinib 
was shown to inhibit both ABCB1 and ABCG2 transporters28, and YM155 is a substrate of ABCB129. Moreover, 
neuroblastoma cell lines resistant to YM155 were shown to express high levels of ABCB130. Neuroblastomas 
are known to express high levels of ABCC1 transporter as well6, 31. Thus we tested whether lapatinib affects the 
intracellular concentration of YM155, using a mass spectrometry based multiple reaction-monitoring assay 
(MS-MRM) (Fig. 2A). We found that treatment with lapatinib increased the intracellular concentration of YM155 
even to a larger extent than cyclosporine, which is a known inhibitor of ABCB1. Conversely, pre-treatment with 
inhibitors of the ABCC1 and ABCG2 transporters (MK-571 and KO143, respectively), did not influence the 
intracellular YM155 levels. These data suggest that the synergy may stem from lapatinib inhibiting ABCB1 and 
thereby enabling the intracellular accumulation of YM155. We, therefore, tested the lapatinib/YM155 combina-
tion in A673 Ewing sarcoma cells, as Ewing sarcoma cells in general have low expression of ABCB1 as reported in 
the Cancer Cell Line Encyclopedia data (CCLE)32. Both SH-SY5Y and A673 express similar amounts of SLC35F2, 
a solute carrier transporter that is responsible for YM155 influx18 (Fig. 2B). Thus, the cell lines are expected to 
have similar capacity to uptake YM155, but a different ability to eliminate it via the ABCB1 transporter. Indeed, 
when we compared the IC50s of YM155 in SH-SY5Y and A673 cells we noted a dramatic difference in sensitivity, 
with values of ~1 nM in A673 but ~250 nM in SH-SY5Y, which can be attributed to differences in levels of ABCB1 
between the two cell lines (Fig. 2C). Furthermore, we observed a mild to strong antagonism between the two 
compounds in Ewing sarcoma cell line (Fig. 2D). Directly assessing the intracellular concentration of YM155 
using the MS-MRM assay we found that neither lapatinib, KO143, nor cyclosporine could influence the intra-
cellular concentration of YM155 in A673 (Fig. 2D). Thus, the strong synergistic effect observed when lapatinib 
and YM155 were combined was inherent to ABCB1 expressing neuroblastoma cells, where ABCB1 inhibition 
by lapatinib augmented YM155 concentrations and cytotoxicity. Finally, we performed a gene functional study, 
where ABCB1 expression in SH-SY5Y cells was downregulated by siRNA in order to assess whether the drug syn-
ergy was dependent on ABCB1 (Fig. 2F). Unlike in cells that express high levels of ABCB1, ABCB1 knockdown 
dramatically suppressed the synergistic effect since similar percentages of apoptotic cells were observed in the 
single drug treated groups and after the combinatorial treatment (Fig. 2G). Thus, we concluded that the enhanced 
cytotoxicity of YM155 is due to the lapatinib interference with the ABCB1 transporter.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 3091  | DOI:10.1038/s41598-017-03129-6
The anti-tumor effect of the combination was confirmed in vivo. To investigate whether the drug 
combination is effective in vivo, we tested the combination in a transgenic zebrafish model, where the overex-
pression of human MYCN in the peripheral sympathetic nervous system induces tumors in the fish analog of the 
adrenal medulla33. These tumors closely resemble human neuroblastoma, and the model has been successfully 
used to study interactions between MYCN and other oncoproteins and the role of developmental pathways in 
neuroblastoma pathogenesis34, 35. We exposed neuroblastoma bearing fish to YM155 and lapatinib for seven days 
Figure 2. Synergistic effect is a consequence of a blocked efflux of YM155 by lapatinib in vitro. The anti-
tumor effect of the combination is confirmed in an in vivo model. (A) Multiple-reaction monitoring assay in 
the SH-SY5Y neuroblastoma cells. Lapatinib inhibits the ABCB1 transporter and allows higher intracellular 
concentration of YM155. Area under the curve (AUC) corresponds to intracellular YM155 levels. Cyclosporine, 
MK-571 and KO143 are inhibitors of ABCB1, ABCC1 and ABCG2 transporters, (respectively). Data are the 
mean ± s.d. of triplicates. (B) Comparison of mRNA expression profiles of SLC35F2 and ABCB1 available in 
CCLE32 between SH-SY5Y and A673 cells. (C) Dose response curves of the effects of YM155 on the viability 
of SH-SY5Y (green) and A673 cells (red). (D) Heatmap of CI values in the combination matrix of YM155 
and lapatinib in A673 cells. Data represent the mean of triplicates. (E) Multiple-reaction monitoring assay in 
A673 cells. Area under the curve (AUC) corresponds to intracellular YM155 levels. Cyclosporine and KO143 
are inhibitors of ABCB1 and ABCG2 transporters, (respectively). Data are the mean ± s.d. of triplicates. (F) 
Efficiency of ABCB1 knock down after 24 hours. (G) Combined effect of ABCB1 knockdown and YM155 and/
or lapatinib treatment on apoptosis of SH-SY5Y cells. Apoptosis was measured in SH-SY5Y cells which were 
transfected with control siRNA or siRNA against ABCB1 (25 nM); and treated with DMSO, 1 μM lapatinib and/
or 15 nM YM155 for 48 hours. Percentages of cell death were used to calculate the fold changes in apoptosis of 
siRNA transfected and drug treated cells compared to untreated siRNA transfected cells. (Mean ± SEM, n = 3, 
**P < 0.01, ANOVA). (H) Analysis of neuroblastoma growth in Tg[dβh:MYCN-EGFP] zebrafish, expressing 
MYCN-EGFP under the control of dopamine-β-hydroxylase promoter. Fish were treated with lapatinib and 
YM155 (2 µM and 6.5 nM, respectively) for 7 days. Zebrafish were imaged before and after treatment with the 
same settings. The fluorescent area behind gills corresponding to tumors (white arrow) were measured by using 
ImageJ (representative images of three independent experiments, n = 3). A quantitation of the results is shown 
in the graph, where each symbol represents a fish (P = 0.0016, paired t test).
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and observed that the tumor size was considerably smaller after the treatment (Fig. 2H). These results prompt a 
further clinical evaluation of this novel combination.
Discussion
YM155 is an anticancer drug which causes DNA damage and survivin downregulation, and therefore was con-
sidered a promising treatment option in neuroblastoma30, 36, 37. However, neuroblastoma cells with high ABCB1 
levels were intrinsically resistant to YM15530. ABC transporters are often upregulated in the most aggressive neu-
roblastoma variants in response to treatment, causing acquired resistance and ultimately leading to therapy inef-
fectiveness12, 31. Performing a factorial matrix-design combinatorial drug screen on the SH-SY5Y neuroblastoma 
cells line we found that the FDA approved EGFR/HER2 tyrosine kinase inhibitor lapatinib strongly synergized 
with YM155. We showed that the synergy occurs in TRKA overexpressing as well as in MYCN overexpressing and 
amplified neuroblastoma cells. The mechanistic basis for the synergy is the blockade of the ABCB1 efflux pump by 
lapatinib. Consequently, the intracellular concentration of YM155 was dramatically increased and its effect poten-
tiated and prolonged upon combination with lapatinib. Moreover, this strong synergy was absent in a low-ABCB1 
expressing Ewing sarcoma cells line. Importantly, the strongest response was observed at concentrations much 
lower than the corresponding in vitro IC50 values each individual drug. Such concentrations are achievable and 
well tolerated in patients for both agents20, 23. Using a zebrafish model system that reproduces human MYCN 
amplified, aggressive neuroblastoma, we could confirm the anti-tumor effect of the combination in an in vivo 
model. Therefore, the combination of lapatinib and YM155 is a promising treatment option for neuroblastoma 
with either intrinsic or acquired ABCB1 upregulation. The elucidation of the mechanistic basis for the synergy, 
i.e. lapatinib inhibiting ABCB1 allowing YM155 to accumulate, also provides a potential biomarker for stratify-
ing patients for treatment. Furthermore, our results suggest that lapatinib should be considered as combination 
therapy for other agents that are eliminated from cells by the ABCB1 transporters.
Materials and Methods
Viability assays. The individual drug effects were determined in proliferation assays using Cell Titer Glo 
(Promega Inc., Madison WI, USA) basically as described previously14. 4 × 10³ cells were seeded in 96-well plates 
in triplicates and treated with drugs 24 h after plating. Serial dilutions in a range between 20 µM and 0.05 µM 
were applied for 72 hours. IC50 values were determined by fitting a dose response curve to the data points using 
non-linear regression analysis utilizing the GraphPad Prism software.
Compounds. Lapatinib was purchased from LC Laboratories (Woburn, MA, USA). YM155 was obtained 
from Selleck Chemicals (Selleckchem, Houston, TX, USA). The full compound library with their respective man-
ufacturers is given in Supplementary Table S1.
Determination of synergy and analysis of the screen. The combination index (CI) was used for the 
quantification of synergistic, antagonistic or additive effects of each drug pair as described previously38. In order 
to capture any synergistic effect, we generated duplicate matrices for each drug pair, positioned in different screen-
ing plates. Cell viability was measured across a range of dose levels for each drug pair without maintaining the 
ratio of dose levels constant. In its conventional terminology, a non-constant ratio experimental design has been 
deployed. Such an experimental setup has been selected for the purposes of attaining a broad screening window 
across drug combinations and concentrations levels. A well-known trade-off of a non-constant dose ratio exper-
imental design is the lack of ability to simulate CI across varying dose levels to estimate a smooth dose-response 
curve. However, it is possible to calculate CI for each combination data point under the non-constant ratio design. 
The evaluated CI has then been mainly employed for classifying drug pairs as synergistic or antagonistic with 
respect to CI cut-offs, thus allowing to detect drug combinations with non-additive effects. Estimating CI for a 
given drug pair at an observed point entails a two-step process. Initially, the kinetic order m and median effect 
dose Dm appearing in median-effect equation (1) are estimated for each single drug. The median-effect equation 
expresses as
=

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where the observables are the fraction of unaffected (viable) cells fu and drug dose D, while fa = 1 − fu is the frac-
tion of affected (inhibited) cells. To apply equation (1) to a single drug, the fa, fu, and D values for that drug are 
taken into account across all drug pairs at the instances of zero dosage for the other drug in each pair. Equation (1) 
is then log-transformed, and simple linear regression is used for estimating m and Dm. The second step involves 
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where Di, (Dm)i are the dose and estimated median dose for drug i, ∈i {1, 2}, in the pair.
Microarrays. SH-SY5Y cells were treated with DMSO, 15 nM YM155, 1 µM lapatinib or the combination 
(15 nM YM155 and 1 µM lapatinib) for 6 hours, in triplicates. RNA was extracted using the Qiagen RNAeasy kit 
according to the manufacturer’s instructions. Total RNA was then used for GeneChip analysis. Preparation of 
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terminally labeled cDNA, hybridization to genome-wide GeneChip Human Gene 1.0 ST Arrays and scanning 
of the arrays were done according to the manufacturer’s instructions (Affymetrix). For differential expression 
analysis, the aroma.affymetrix and the Bioconductor Limma packages were used. Empirical Bayes approach was 
applied, while the Benjamini and Hochberg method was used for false discovery control; a false discovery rate of 
0.05 was selected, providing an adjusted p.value (q.value).
Colony formation assay. 1 × 104 cells per well were seeded in six-well plates (in triplicates). Next day the 
cells were treated with either DMSO (equal to the highest amount of compound dilution, maximum 0.2%) or 
compounds at combination concentrations. Cells were incubated at 37 °C, 5% CO2 for 7–10 days. Medium was 
aspirated, cells were washed with PBS (Gibco), stained with crystal violet solution (0.5% in 6% glutaraldehyde) 
and left to dry overnight. For quantification of results, ultraviolet absorbance of crystal violet was determined 
at 570 nm following solubilization by 70% ethanol. Data were analyzed using the ANOVA single factor analysis 
followed by ad hoc Tukey test.
Cell culture. The SH-SY5Y and SH-SY5Y NTRK1 tetracycline (Tet)–inducible cell lines, SH-SY5Y MYCN 
tetracycline (Tet)–inducible, IMR5–75 cell lines and A673 cell lines were received as generous gifts from Drs. 
Frank Westermann, Johannes Schulte and Javier Alonso. A673 cells were cultured in DMEM (Sigma) media 
containing 10% fetal bovine serum and 10 U mL−1 penicillin/streptomycin (Gibco). SH-SY5Y and IMR5–75 
cells were cultured in RPMI 1640 (Sigma) media containing 10% fetal bovine serum and 10 UmL−1 penicillin/
streptomycin (Gibco).
Antibodies used for immunoblotting. Rabbit anti-actin (AAN01) (Cytoskeleton, AAN01), mouse 
anti-tubulin (DM1A) (Abcam, ab7291), mouse GAPDH (Santa Cruz, sc-365062), mouse N-Myc (Santa Cruz, 
sc-53993), rabbit phospho-TRKA (Tyr674/675)/TrkB (Tyr706/707) (C50F3) (Cell Signaling, 4621S), rabbit TRK 
(C14) (Santa Cruz, sc-11).
Determination of intracellular drug levels via MS-MRM. 2 × 105 cells were treated with drugs at 37 °C 
as indicated. Subsequently, cells were washed three times with ice-cold PBS and extracted directly with 300 μl 
80% ice-cold methanol. Extracts were cleared by centrifugation for 20 min at 4 °C at 16,000 g, and supernatants 
were used for subsequent MS quantifications by MS (Waters Xevo TQ system). MRM settings were automatically 
generated for every compound using the IntelliStart software (Waters), and quantification was conducted on the 
basis of the intensity of three daughter ions.
RNA Interference. The ABCB1 Silencer siRNA (siRNA ID: 4029) and non-targeting control siRNA were 
obtained from Ambion. Transfections were performed using the JetPrime reagent (Polyplus Transfection) accord-
ing to the manufacturer’s instructions. Cells were lysed after 24 hours for Western blot analysis to test the effi-
ciency of knockdown.
Apoptosis Assay. After the drug treatments, cells were fixed in ethanol and stained with propidium iodide, 
as previously described39. Apoptosis was measured by identifying the sub-G1 population using an Accuri C6 flow 
cytometer (BD).
Zebrafish experiments. Zebrafish experiments were approved by the UCD Animal Research Ethics 
Committee and the Healthcare Products Regulatory Authority (AE18982/P038). All methods were performed 
in accordance with the relevant guidelines and regulations. The transgenic Tg[dβh:MYCN-EGFP] zebrafish line 
was a generous gift from Prof. A. Thomas Look (Dana-Farber Cancer Institute, Harvard Medical School)33. Adult 
Tg[dβh:MYCN-EGFP] zebrafish (Danio rerio) were maintained on a 14 h light/10 h dark cycle at 28 °C; and moni-
tored for fluorescent tumor masses every two weeks. Approximately 20% of fish develop the equivalent of human 
neuroblastoma by about 8 months of age33. Drug treatments of zebrafish were performed as described earlier40. 
Zebrafish developing tumors (age: 21 months; n = 3) were treated with YM155 and lapatinib every 72 hours for a 
total of seven days. Fish water was changed every 72 hours, and drugs were dissolved in the fish water. Zebrafish 
were anesthetized by 0.016% Tricaine prior to microscopic analysis. An Olympus SZX10 fluorescent stereo micro-
scope equipped with an Olympus DP71 camera was used to capture images. The fluorescent area posterior to 
the gills, which corresponds to the region of neuroblastoma growth33, was analysed using the ImageJ software 
(v1.44p).
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